Clinical Trials

Several clinical trials recorded in the registry evaluate conditions including post-cancer hematological follow-up, neurodevelopmental and physical disabilities, post-surgical atelectasis, and SARS-CoV-2-associated acute respiratory distress syndrome. Categorized under unspecified or Not Applicable phases, these observational or non-interventional studies feature recruitment statuses ranging from not yet recruiting to completed. Sponsorship is led by academic centers and hospital networks, including Hospices Civils de Lyon, the Chinese University of Hong Kong, the National and Kapodistrian University of Athens, and Centre Hospitalier Universitaire Dijon.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06007794 Not yet recruiting
Cancer|Post-cancer|Hematology
Hospices Civils de Lyon
 2024-04-01 Not Applicable
NCT06112483 Not yet recruiting
Specific Learning Disorder|Intellectual Disability Mild to Moderate|Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder|Physical Disability
Chinese University of Hong Kong
 2023-11-15 --
NCT06203665 Completed
Atelectasis|Compliance Patient
Panagiota Griva|National and Kapodistrian University of Athens
 2023-06-07 Not Applicable
NCT05594550 Not yet recruiting
Acute Respiratory Distress Syndrom (SARS-Cov 2)
Centre Hospitalier Universitaire Dijon
 2022-10 --

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 1V209 (TLR7 agonist T7) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

1V209 selectively binds to and activates Toll-like receptor 7 (TLR7), triggering downstream NF-κB and interferon regulatory factor signaling cascades that stimulate the secretion of type I interferons and pro-inflammatory cytokines. This cellular activation enhances antigen-specific humoral and cell-mediated immune responses, resulting in immunogenic tumor suppression that aligns with its clinical evaluation in cancer, post-cancer, and hematologic conditions.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.